After 68 weeks on semaglutide 2.4 mg, roughly 86% of participants in STEP-1 had lost at least 5% of body weight, but that means 14% did not reach even that modest threshold
That is why our GLP-1 Weight Loss Program is designed to be physician-led, personalized, and supported by more than medication alone
When stored outside recommended temperature ranges specified in FDA labeling, these medications may experience reduced efficacy, potentially leading to suboptimal glycemic control or inadequate weight management
Notably, ASC30 is the first incretin demonstrating effective weight loss across multiple formats: once-daily oral dosing, once-monthly treatment injections, and potential once-quarterly maintenance dosing
Benefits and Limitations: What Patients Commonly Report Patient reports and clinical trial data are different categories
Most of this weight loss is likely to occur within the first 32 weeks